Thursday, August 18, 2022 7:54:20 AM
5:49 pm ET August 17, 2022 (Benzinga) Print
Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186RNL for leptomeningeal metastases.
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it was awarded a $17.6 million Product Development Research grant by the Cancer Prevention and Research Institute of Texas (CPRIT) to fund the continued development of the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with leptomeningeal metastases (LM).
"The Plus team is honored to receive this significant and esteemed award from CPRIT," said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. "We expect that the non-dilutive funding from CPRIT will come on-line next month once the award agreement is finalized and this will significantly offset our longer-term, three-year capital requirements for the advancement of our LM program."
In the second quarter of 2022, the Company completed enrollment of Cohort 1 in the ReSPECT-LM Phase 1/2a dose escalation trial (NCT05034497). 186RNL was delivered without dose limiting toxicities in this initial cohort, and the independent Data and Safety Monitoring Board has approved the plan to move ahead with Cohort 2.
"LM is one of the most devastating and aggressive late-stage cancer complications, in which the primary cancer spreads to the central nervous system. The most common solid tumor giving rise to LM is breast cancer and LM affects 3% to 5% of women already suffering with breast cancer," stated Jamil Rivers, President of METAvivor Research and Support, Inc. "The continued investment in clinical research and development for metastatic breast cancer, including leptomeningeal
New York Yankees and Duke Basketball
Recent PSTV News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/07/2024 09:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:02:15 PM
- Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT • GlobeNewswire Inc. • 06/07/2024 11:30:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/05/2024 11:26:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:16:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 11:00:11 AM
- Plus Therapeutics Announces New Employment Inducement Grants • GlobeNewswire Inc. • 05/17/2024 09:00:00 PM
- Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/15/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:01:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:00:50 PM
- Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024 • GlobeNewswire Inc. • 05/13/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 11:30:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 11:30:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 11:30:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 11:30:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 11:30:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 11:30:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:20:34 PM
- Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial • GlobeNewswire Inc. • 05/09/2024 03:29:23 PM
- Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial • GlobeNewswire Inc. • 05/08/2024 09:35:00 PM
- Plus Therapeutics Announces Private Placement Financing of up to $18 Million • GlobeNewswire Inc. • 05/06/2024 11:30:00 AM
- Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense • GlobeNewswire Inc. • 04/22/2024 11:00:00 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/08/2024 09:30:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:04:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:01:48 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM